Navigation Links
Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
Date:10/27/2010

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly ADP-Ribose Polymerase (PARP) inhibitor drug class.  

The Pharmacor 2010 findings from the topic entitled Breast Cancer reveal that Sanofi-Aventis's PARP inhibitor iniparib has the potential to achieve blockbuster peak-year sales in excess of $1 billion. In addition to iniparib, other key PARP inhibitors in development include AstraZeneca's olaparib and Abbott Laboratories' veliparib. Sales of agents targeting HER2-positive breast cancer will increase by almost $2 billion through 2019. This growth will be fueled by the increased uptake of Roche/Chugai's Herceptin, GlaxoSmithKline's Tykerb/Tyverb and the approval of three new HER2-targeted therapies -- Roche/Genentech/Chugai's trastuzumab-DM1, Roche/Chugai's Omnitarg and Pfizer's neratinib.

The Pharmacor 2010 findings also reveal that Roche/Genentech/Chugai's Avastin has garnered substantial patient share, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where effective therapies are few. However, in July 2010, Avastin's future in this indication was cast in doubt after the Oncologic Drugs Advisory Commission recommended that the FDA rescind the agent's conditional approval for first-line metastatic HER2-negative breast cancer. Additionally, Avastin's European label for breast cancer is also under review by the European Medicines Agency.

"The fact that the National Comprehensive Cancer Network guidelines panel for breast cancer recently affirmed its existing recommendation for Avastin is a positive sign for Roche. However, even in the event that Avastin manages to hang on to a first-line metastatic breast cancer label it's sales -- which surpassed $1 billion for breast cancer alone in 2009 in the world's major markets -- will plummet over the next several years," said Decision Resources Analyst Niamh Murphy, Ph.D. "By 2019, sales of Avastin in breast cancer will drop to $350 million as a result of oncologists' diminishing confidence in the agent, increased prescribing and reimbursement restrictions and competition from emerging therapies -- most notably, iniparib and Eli Lilly's VEGF inhibitor, ramucirumab."

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
2. FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
3. Nanoelectronic transistor combined with biological machine could lead to better electronics
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
6. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
7. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
8. Microbix Has Best-Ever Quarterly Sales
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
11. Dynamic Ventures Corporation enters into a long-term agreement that brings $50 million annual sales opportunity for wholly owned subsidiary EZ-Build.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):